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Background: Resistance to Fas-mediated apoptosis limits the efficacy of currently available chemotherapy regimens. We
identified CD74, which is known to be overexpressed in hematological malignancies, as one of the factors interfering with
Fas-mediated apoptosis.
Methods: CD74 expression was suppressed in human B-lymphoma cell lines, BJAB and Raji, by either transduction with
lentivirus particles or transfection with episomal vector, both encoding CD74-specific shRNAs or non-target shRNA. Effect
of CD74 expression on Fas signaling was evaluated by comparing survival of mice hydrodynamically transfected with
vector encoding full-length CD74 or empty vector. Sensitivity of cells with suppressed CD74 expression to FasL, edelfosine,
doxorubicin, and a humanized CD74-specific antibody, milatuzumab, was evaluated by flow cytometry and compared to
control cells. Fas signaling in response to FasL stimulation and the expression of Fas signaling components were
evaluated by Western blot. Surface expression of Fas was detected by flow cytometry.
Results: We determined that cells with suppressed CD74 are more sensitive to FasL-induced apoptosis and Fas
signaling-dependent chemotherapies, edelfosine and doxorubicin, than control CD74-expressing cells. On the
other hand, expression of full-length CD74 in livers protected the mice from a lethal challenge with agonistic
anti-Fas antibody Jo2. A detailed analysis of Fas signaling in cells lacking CD74 and control cells revealed increased
cleavage/activation of pro-caspase-8 and corresponding enhancement of caspase-3 activation in the absence of
CD74, suggesting that CD74 affects the immediate early steps in Fas signaling at the plasma membrane. Cells with
suppressed CD74 expression showed increased staining of Fas receptor on their surface. Pre-treatment with
milatuzumab sensitized BJAB cells to Fas-mediated apoptosis.
Conclusion: We anticipate that specific targeting of the CD74 on the cell surface will sensitize CD74-expressing
cancer cells to Fas-mediated apoptosis, and thus will increase effectiveness of chemotherapy regimens for
hematological malignancies.Background
CD74, better known as an invariant chain (Ii) of the major
histocompatibility complex II (MHC II) [1-3], is indispens-
able for the proper development of B cells. CD74 is
internalized into the endocytic compartment, where intra-
membrane cleavage releases the intracellular cytosolic do-
main (CD74-ICD). CD74-ICD then enters the nucleus,
activates NF-kB p65/RelA, and controls the differentiation
of B cells through the TAFII105 coactivator [4,5]. CD74-
ICD also induces expression of TAp63, which subsequently* Correspondence: fsamaniego@mdanderson.org
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unless otherwise stated.elevates expression of Bcl-2 and promotes survival of B
cells [6]. Macrophage migration inhibitory factor (MIF) is
the assigned ligand for CD74 and its binding activates the
extracellular signal-regulated kinase-1/2 (ERK 1/2) MAP
kinase (MAPK) cascade and cell proliferation [7], as well
as NF-κB, through which it enhances the expression of
Bcl-2 [6].
CD74 expression is rather limited in normal human
tissues, but it was found to be overexpressed in more
than 85% of non-Hodgkin lymphoma (NHL), chronic
lymphocytic leukemia (CLL) and a majority of multiple
myeloma (MM) cells [8-12]. B cells from CLL patients
have higher cell surface levels of CD74 than do normal
B cells, and it was shown that the activation of CD74l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tion of IL-8, which promotes cell survival and tumor
progression [11,13]. CD74-mediated proliferative and
pro-survival signaling can initiate or contribute to pro-
carcinogenic events and enhance the survival of cancer
cells.
The Fas receptor is widely expressed by many tissues, yet
the extent of Fas-mediated apoptosis does not correlate
with the extent of Fas expression. Hematological cancer
cells are commonly resistant to Fas ligand (FasL)-induced
apoptosis despite normal expression of the Fas receptor
[14]. This resistance is usually not caused by Fas/FasL mu-
tations or overexpression of apoptosis inhibitors, such as
cFLIP (cellular FLICE/caspase-8-inhibitory protein) [15].
Identification of potential inhibitors of Fas-mediated apop-
totic signaling in cancers and understanding of the mech-
anism involved are important steps necessary for the design
and implementation of new targeted therapies. Reversing
Fas resistance has become a primary interest in order to
improve the efficacy of treatments for chemotherapy-
resistant hematological cancers [16-19]. Several current
treatments, like interferon gamma (IFN-γ), CD40L, and ri-
tuximab, are believed to improve responses to chemother-
apy primarily through restoration of Fas apoptotic signaling
[16,17,20,21]. Our goal was to identify and to target inhibi-
tors of the Fas receptor in order to reinstate Fas-mediated
apoptotic signaling in cancer cells with limited off-target ef-
fects on normal cells.
In the light of well documented CD74-mediated pro-
survival effects, we aimed to examine the effect of CD74
on Fas-mediated apoptosis, which is required for effect-
ive killing of cancer cells by most chemotherapies and
radiation [22-26].
Methods
Cell lines and drug treatments
BJAB, Raji, Ramos, Daudi, and Jurkat cells were purchased
from ATCC and grown in RPMI medium with 10% FBS
(HyClone) in a 5% CO2 atmosphere at 37°C, and split 2–3
times per week. Cell lines were authenticated by STR ana-
lysis (MD Anderson Cancer Center Characterized Cell
Line Core) and regularly tested for mycoplasma (Lonza).
For drug treatment, 0.5e6 cells/mL in RPMI + 5% FBS
were seeded into 24-well plates and treated with indi-
cated doses of FasL (Enzo) or edelfosine (Sigma-
Aldrich) for 20 hours, doxorubicin (Sigma-Aldrich) for
48 h, or 10 ng/mL of super FasL (sFasL; Enzo) for 16 h.
BJAB cells (1e6 cells/mL) were incubated with 50 μg/mL
of milatuzumab (humanized anti-CD74 antibody, hLL1;
Immunomedics, Inc.) for 10 min prior to addition of 20 μg/
mL of goat anti-mouse or goat anti-human IgG (both from
Jackson ImmunoResearch). Cells were washed after 30 min
and subsequently incubated with either 50 ng/mL of anti-
Fas antibody CH-11 (Millipore) or recombinant FasL (Enzo).Cells were harvested 24 h later and analyzed for apoptosis
by propidium iodide staining and flow cytometry, as de-
scribed previously [27].
Cloning and RNA interference
To knock-down CD74 expression, BJAB and Raji cells
were transduced using MISSION shRNA lentiviral parti-
cles targeting CD74 or non-target (NT) controls, accord-
ing to manufacturer’s protocol (Sigma-Aldrich), and kept
under selection with 1.9 μg/mL of puromycin.
The shRNA sequences from MISSION shRNA lentiviral
particles were inserted between BamHI and EcoRI restric-
tion sites in the multiple cloning cassette of pSIREN-
Shuttle vector (Clontech). The U6 promoter-shRNA
cassettes were then recloned to KpnI and ApaI sites of
the pEPI-1 vector kindly provided by Dr. A. C. Jenke
(HELIOS Children's Hospital Wuppertal, Germany)
[28]. The correct sequences of inserted shRNAs were
confirmed by sequencing (SeqWright).
Obtained plasmids were transfected into cells using
Lipofectamine 2000 transfection reagent (Invitrogen) ac-
cording to the manufacturer’s recommendations. Trans-
fected cells were sorted 48 h post transfection based on
green fluorescent protein (GFP) expression, using a flow-
activated cell sorter BD FACSAria II (BD Biosciences)
followed by limited dilutions and selection with geneticin
(1350 μg/mL; Invitrogen) for 2 weeks.
Western Blotting (WB)
WB was performed according to standard protocols, as
described previously [29,30]. Protein expression in total
cell lysates was analyzed with primary antibodies recog-
nizing Fas (B-10), CD74 (LN-2), cFLIP, caspase-8 and
caspase-3 [all at 1:1,000 dilution in 5% blotting-grade
blocker (BioRad) in phosphate-buffered saline (PBS)
with Tween 20], followed by anti-mouse-HRP or anti-
rabbit-HRP antibodies when an unconjugated primary
antibody was used. Equal loading was verified by β-actin-
HRP antibody (1:10,000; Sigma-Aldrich). Visualization was
achieved by Supersignal West Pico chemiluminescent sub-
strate (Thermo Scientific). Intensity of bands was compared
by densitometry using ImageJ software (NIH).
Flow cytometry
For detection of surface Fas or CD74, cells were washed
with 2% FBS/PBS and blocked with 0.025 mg/mL of mouse
IgG blocking reagent (Invitrogen) at 4°C for 15 min in the
dark and washed once with 2% FBS/PBS. Cells were then
incubated with 3 μL of PE-conjugated anti-Fas antibody
UB2 or with FITC-conjugated anti-CD74 antibody M-B741
(both from BD Biosciences) in 50 μL of 2% FBS/PBS at 4°C
for 20 min in the dark. After washing cells 2× with 2% FBS/
PBS, flow cytometry was performed on an BD LSRFortessa
flow cytometer with Diva software (BD Bioscience).
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collected and resuspended in 1 mL of cold 1% FBS/PBS
and stained with Vybrant® Apoptosis Assay Kit #5 ac-
cording to protocol provided by the manufacturer (Mo-
lecular Probes). Flow cytometry was performed on BD
FACSCanto II flow cytometer with Diva software (BD
Bioscience). Data were analyzed using FlowJo software
(Tree Star Inc.).
Animal experiments and immunohistochemistry
All animal experiments were performed in accordance
with the guidelines of MD Anderson Cancer Center’s In-
stitutional Animal Care and Use Committee. C57BL/6
mice (6- to 8-weeks old; from the National Cancer Insti-
tute) were hydrodynamically transfected [31] with
100 μg of plasmid (pEF4-myc or pEF4-CD74-myc [4];
kindly provided by Dr. Idit Shachar, The Weisman Insti-
tute of Science, Rehovot, Israel). Mice were challenged
with agonistic anti-Fas antibody Jo2 (0.4 μg/g; BD Bio-
sciences) 24 h post transfection and monitored for sur-
vival up to 6 h post challenge. Livers were harvested at
the time of death/sacrifice, paraffin embedded, and cut
to 5 μm sections.
Formalin-fixed, paraffin-embedded liver tissue sections
on microscope slides were treated with an unmasking
kit (1:500; Vector Laboratories). Sections were then
stained with hematoxylin and eosin (H&E; both from
Fisher Scientific). Immunohistochemical staining was
performed using a mouse monoclonal anti-myc antibody
(1:500; Sigma-Aldrich) and a rabbit polyclonal anti-cleaved
caspase-3 antibody (1:500; Cell Signaling), followed by
staining and developing with an ABC staining kit (Vector
Laboratories), according to manufacturer’s protocol.
Stained samples were viewed using a Zeiss Axioskop 2 plus
microscope (Carl Zeiss) with 4× and 20× magnification
objectives.
Statistical analysis
Differences between groups were calculated using the
two-tailed Student t test. P-values less than 0.05 were
considered statistically significant.
Results
CD74 expression in lymphoma cell lines can be
suppressed by shRNAs
To study the effects of CD74 on Fas-mediated apoptosis,
we first tested CD74 expression in 4 B-lymphoma cell
lines (BJAB, Ramos, Raji, and Daudi) and in the Jurkat (T-
cell leukemia) cell line by WB. All four B-lymphoma cell
lines expressed CD74, with the lowest expression in Ra-
mos cells (Figure 1A). Daudi cells expressed CD74, but
they are known to lack Fas on the cell surface [32]. Thus,
the BJAB and Raji cell lines were selected for further
analysis.CD74 expression was first suppressed by transduction
of cells with lentiviral particles encoding CD74-targeting
shRNAs (#35, #36, #37, #39) or non-target control
shRNA (NT). Cells transduced with particles encoding
shRNA 35 and 36 showed a significant decrease of total
cellular CD74 (Figure 1B) and surface CD74 (data not
shown) when compared to NT shRNA controls. To ex-
clude possible effects of a random incorporation of lenti-
viral sequences into the genome, we recloned CD74-
targeting shRNAs 35 and NT into a mammalian-based
episomal vector pEPI-1, which was shown previously to
generate stable knock-downs without incorporation into
the genome [28]. The generated pEPI-shRNA-35 and -NT
plasmids were used to generate stable CD74 knock-downs
in BJAB cells, BJAB Epi 5.7 and N.7 (Figure 1B).
Downregulation of CD74 sensitizes cells to Fas-mediated
apoptosis and to Fas-dependent chemotherapeutic
agents
The pro-survival and anti-apoptotic effects of CD74 are
well documented. We thus explored the effects of CD74
downregulation on Fas-mediated apoptosis that plays an
important role in responses to chemotherapy.
Cell lines were also tested for their sensitivity to super-
FasL. All 3 pairs of CD74 knock-down and control (non-
target) cells showed significantly increased sensitivity of
CD74 knock-down cells to Fas-mediated apoptosis
(Figure 2A) independently of the method used to generate
the knock-downs (episome vs. lentivirus). Importantly,
there were no significant differences in FasL-induced
apoptosis between pairs of BJAB Epi (N.7 vs 5.7) and BJAB
Lenti (NT vs. 35) cells (18 ± 0.1% vs. 36 ± 3.3% and 20 ±
1.5% vs. 35 ± 0.1%, respectively; both pairs P < 0.01). Be-
cause downregulation of CD74 using episomal vector
(BJAB Epi 5.7) turned out to be more stable than lentiviral
particles (BJAB Lenti 35 and Raji Lenti 35; data not
shown), BJAB Epi cells were selected for all subsequent
experiments.
Incubation of BJAB Epi cells with increasing doses
of FasL revealed that cells with downregulated CD74
were more sensitive to Fas-mediated apoptosis than con-
trol (non-target) cells at all tested FasL concentrations
(Figure 2B), without significant differences in basal apop-
tosis (0 ng/mL of FasL).
Edelfosine was shown to kill cancer cells by a ligand-
independent crosslinking of Fas receptor [33]. We thus
tested the effect of CD74 downregulation on edelfosine-
induced cell killing. As expected, cells lacking CD74
were sensitized to the standard (10 μM) dose of edelfo-
sine when compared to control (non-target) cells (64 ±
1% vs. 36 ± 7%; P < 0.001) (Figure 2C).
Doxorubicin (DOX) is a very potent anti-cancer drug
used to treat lymphoma and other cancers. It is well
known that cells with defective Fas signaling are
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Figure 1 Establishment of CD74 knock-down cells. (A) Indicated lymphoma cell lines were harvested, lysed and CD74 expression was
detected by WB using anti CD74 antibody LN-2. β-actin staining was used as a loading control; (B) BJAB Lenti and Raji Lenti cell lines with CD74
expression knocked-down with lentiviral vectors encoding CD74 targeting shRNAs (Sigma-Aldrich, 35, 36, 37, 39) or no-target shRNA (NT) and
BJAB Epi cells with shRNAs expressed from the episomal vector (CD74 knock down cells clone 5.7, no-target cells clone N.7 and parental
cells - Par) were harvested, lysed and analyzed for the expression of CD74 as in (A).
A B
C D
Figure 2 Suppression of CD74 expression sensitizes lymphoma cell lines to Fas-mediated apoptosis and Fas-dependent chemotherapies.
Cell death was evaluated by flow cytometry in (A) BJAB Epi (clones 5.7 and N.7), BJAB Lenti (clones 35, NT), Raji Lenti (clones 35, NT) cells treated with
20 ng/mL of superFasL for 20 hours, (B) BJAB Epi clones 5.7 (solid line) and N.7 (dashed line) treated with indicated concentration of FasL for 20 hours,
(C) BJAB Epi clones 5.7 (solid line) and N.7 (dashed line) treated with indicated concentration of edelfosine for 20 hours; (D) BJAB Epi clones 5.7 (solid
line) and N.7 (dashed line) were treated with indicated concentrations of doxorubicin for 48 hours. Values shown represent the average and standard
deviation from 3 wells. Presented results are a representative of at least two independent experiments.
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were enhanced in cells lacking CD74 (Figure 2D). Not-
ably, cell death induced by 125 nM DOX in CD74
knock-down cells was comparable to cell death induced
by 500 nM DOX in control (no-target) cells (48.2 ± 5.3%
vs. 52.00 ± 1.3%; P = 0.8).Overexpression of CD74 confers resistance to Fas-
mediated apoptosis
The expression of Fas receptor in the liver tissue is very
high, which makes liver extremely sensitive to Fas-mediated
apoptosis and injection of Fas agonists into mice causes
death due to hepatic failure [34].
We used hydrodynamic transfection to transiently express
CD74 in mouse livers [31]. Subsequent challenge with a le-
thal dose of anti-Fas antibody Jo2 killed all 5 Myc-tag
vector- transfected mice, while 5 of 6 mice transfected with
plasmid encoding Myc-tagged CD74 (CD74-Myc) remained
alive at the end of the experiment, 6 h post challenge
(Figure 3A; P = 0.015). Livers of vector-transfected mice
challenged with Jo2 appeared dark and swollen due to inten-
sive diffuse hemorrhaging, whereas livers of mice expressing




Figure 3 Over-expression of CD74 protects mice from a lethal dose o
plasmid (vector) or plasmid encoding Myc-tagged CD74 using a hydrodyn
were challenged with a lethal dose of agonistic anti-Fas antibody Jo2 and
6 hours; (B) gross appearance of livers from Jo2 challenged mice; (C) immu
Jo2-challenged (vector with Jo2 and CD74-Myc with Jo2) mice. H&E – hem
3 – apoptosis staining.Hematoxylin and eosin (H&E) staining of the har-
vested liver tissues confirmed extensive vs. limited hem-
orrhaging in vector- vs. CD74-Myc-expressing livers
challenged with Jo2 (Figure 3C; H&E). Expression of
CD74-Myc in transfected livers was confirmed by immu-
nohistochemistry using anti-Myc antibody (Figure 3C;
Myc). Further magnification confirmed positive staining
in polygon-shaped cells that contained centrally located
nuclei, characteristics of hepatocytes [Figure 3C; Myc(6×
zoom)].
Staining of liver sections with anti-cleaved caspase-3 anti-
body to evaluate apoptosis revealed higher staining intensity
in the livers of vector-transfected mice compared to CD74-
Myc-transfected livers (Figure 3C; Cleaved Caspase-3),
confirming that expression of CD74 interferes with Fas-
mediated apoptosis.
Downregulation of CD74 enhances processing of
pro-caspase-8
To pinpoint which step in the Fas-mediated apoptosis
cascade is affected by CD74, we treated CD74-deficient
BJAB Epi 5.7 and control BJAB Epi N.7 cells with sFasL,
and analyzed the processing/activation of the initiator
caspase-8 and the executioner caspase-3 by WB
(Figure 4A). This analysis revealed that the activation off agonistic Fas antibody. Mice were transfected with an empty
amic transfection method. Twenty-four hours post transfection, mice
monitored for survival up to 6 hours. (A) Survival of challenged mice at
nohistochemistry of liver tissues from control (vector) and
atoxylin and eosin staining, MYC – Myc-tag staining, Cleaved Caspase
D
P< 0.0027
Fluorescence Intensity - Fas
B A 
C   
Figure 4 Knock-down of CD74 sensitizes lymphoma cell lines to Fas-mediated apoptosis and increases Fas receptor levels on the cell
surface. (A) BJAB Epi cells (clones 5.7 and N.7) were treated with 20 ng/mL of super FasL (sFL) or buffer (C) for 20 hours. Cells were harvested,
lysed and processing of caspase-8 and caspase-3 was detected by Western blot using antibodies specific for cleaved forms of either caspase.
β-actin staining was used as a loading control; (B) BJAB Lenti and Raji Lenti cell lines (clones 35, NT) and BJAB Epi cells (clones 5.7 and N.7) were
harvested, lysed and analyzed for the expression of cFLIPL and pro-caspase-8 using specific antibodies. β-actin staining was used as a loading
control; (C) BJAB Epi cells (clones 5.7 and N.7) were stained with PE-conjugated anti-Fas antibody UB2 and analyzed by flow cytometry. Data
shown are representative of 3 independent experiments; (D) graphic representation of flow cytometry analysis of BJAB Epi cells (clones 5.7 and
N.7) stained with PE-conjugated anti-Fas antibody UB2 and positively selected for green fluorescent protein signal. Values shown represent means
and standard deviations from 3 wells.
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caspase-3 were enhanced in cells lacking CD74. This re-
sult suggests that CD74 interferes with an early mem-
brane proximal step in the Fas signaling cascade that
affects activation of caspase-8.
The membrane proximal signaling of Fas receptor can
be affected by the levels of Fas receptor expressed on the
cell surface and/or the efficiency of ligand binding, as
well as by the inhibitor of caspase-8, cFLIP. We first fo-
cused our attention to the levels of cFLIP, expression,
which is known to be upregulated by NF-κB that was
shown to be activated by CD74 [6]. Comparison of pro-
tein levels in whole cell lysates from CD74 knock-down
and control (non-target) cells by WB analysis showed
that CD74 downregulation did not significantly affect
steady-state levels of cFLIPL in BJAB Epi or Lenti cells
when compared to control cells (Figure 4B). The levels
of cFLIPL target, caspase-8, were also not affected by the
CD74 knock-down (Figure 4B). This result suggested
that increased sensitivity to Fas-mediated apoptosis in
CD74 downregulated cells is not due to decreased ex-
pression of cFLIPL or increased expression of caspase-8.We next compared the levels of Fas receptor expressed
on the surface of the cells by flow cytometry, which re-
vealed significantly elevated levels of surface Fas in
CD74 dowregulated BJAB Epi cells compared to control
(non-target) cells (Figure 4C-D). Similar results were ob-
tained in BJAB Lenti and Raji Lenti cells, which showed
17.1 ± 5.5% and 14.4% increases in the MFI in CD74
knock-down cells, respectively.
Pre-treatment of cells with crosslinked anti-CD74
antibody sensitizes cells to Fas-mediated apoptosis
We next tested the ability of the humanized anti-CD74
antibody (hLL1; milatuzumab) to sensitize BJAB cells to
Fas-mediated apoptosis. Pre-treatment of cells with
hLL1 combined with crosslinking antibody potentiated
apoptotic responses to agonistic Fas antibody CH-11, as
well as FasL (Figure 5).
Discussion
In the presented study we evaluated the effect of CD74 on
the Fas-mediated apoptotic signaling in lymphoma cells
by knocking down the expression of CD74 in BJAB and
Figure 5 Pre-treatment with crosslinked anti-CD74 antibody
sensitizes BJAB cells to Fas-mediated apoptosis. BJAB cells were
treated with anti-CD74 antibody hLL1 crosslinked with goat
anti-mouse (GAM) or anti-human (GAH) IgG followed by 50 ng/ml of
either agonistic anti-Fas antibody CH-11 or FasL. Apoptosis was
analyzed by flow cytometry after 24 hours. Presented values
represent means and standard deviations from 3 different wells.
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cell lines with stable knock-down of CD74 expression by
lentiviral and episomal vectors expressing CD74-targeting
shRNA (Figure 1B). Using these cell lines, we showed that
removal of CD74 sensitizes cells to Fas-mediated
apoptosis (Figure 2A-B) and subsequently also to Fas-
dependent chemotherapies, doxorubicin and edelfosine
(Figure 2C-D). On the other hand, the overexpression of
CD74 in mouse livers protected mice from the lethality of
agonistic Fas antibody Jo2 (Figure 3A) by interfering with
apoptotic signaling (Figure 3C). Increased sensitivity to
Fas-mediated apoptosis in cells lacking CD74 was due
to increased activation/cleavage of the initiator caspase-
8 and correspondingly increased activation of effector
caspase-3 (Figure 4A). These results suggested that the
enhancement of Fas-mediated apoptosis occurs at an
immediate early step of Fas signaling at the plasma
membrane – the activation of death-inducing signaling
complex (DISC). MIF signaling through CD74 mediates
activation of NF-κB, which is known to regulate expression
of cFLIP, a well-known inhibitor of a DISC component
caspase-8. However, the WB analysis of the steady-state
levels of cFLIP and caspase-8 in control and CD74 knock-
down cells did not reveal significant alterations of either
cFLIP or pro-caspase-8 levels (Figure 4B), suggesting
that the Fas signaling component responsible for the
sensitization event due to CD74 removal being upstream
of DISC assembly. We next tested and confirmed that re-
moval of CD74 significantly increased the levels of Fas
receptor at the cell surface (Figure 4C-D) and thus the
amount of the Fas receptor available for activation. More-
over, pre-treatment of cells with crosslinked anti-CD74
antibody sensitized cells to Fas-mediated apoptosis
(Figure 5).The inherent or acquired chemoresistance is a com-
mon hindrance to the successful treatment of cancer.
Multiple chemotherapies, including doxorubicin, have
been shown to upregulate Fas and/or FasL in order to
achieve their full effectiveness [24,25,35-39]. However,
cancer cells frequently downregulate the key players in
the Fas signaling cascade or upregulate apoptosis inhibi-
tors (cFLIP, IAPs, and Bcl-2 family members) to avoid
apoptosis [30,40,41]. Recently, a new category of Fas in-
hibitors has been recognized; cell surface receptors
HGFR/c-MET, human herpesvirus-8 K1, CD44v6/v9,
and nucleolin can bind and block the initiation of Fas
signaling at the plasma membrane [27,29,42-44].
The increasing body of evidence points to CD74, known
as the invariant chain of the major histocompatibility com-
plex II (MHC II), functioning apart from that at MHC II. It
was shown that CD74 serves as a receptor for the macro-
phage migration inhibitory factor, MIF. MIF-binding to
CD74 activates the extracellular signal-regulated kinase-1/2
MAP kinase cascade and cell proliferation [7]. CD74 is
overexpressed in a wide variety of cancers (gastric, thymic,
colorectal, breast, renal and lung carcinomas, invasive
thymomas, bladder, prostate and pancreatic cancers)
[9,12,45-50]. Additionally, the vast majority of NHL, CLL,
and MM express CD74 while limited expression is ob-
served in normal hematopoietic tissues [8-12]. In CLL cells,
MIF was shown to activate NF-κB signaling, promoting the
expression of IL-8 and consequently cell survival [11,13].
The surface expression levels of CD74 in hematological
cancer cells and some solid tumors correlate with poor
prognosis [45,51,52].
A rapid internalization of CD74 (106 to 107 molecules/
cell/day) in a wide range of cancer cells [53], which is not af-
fected by the binding of the mouse monoclonal anti-CD74
antibody LL1 [54], give rise to several therapeutic ap-
proaches. LL1 linked with different radioisotopes greatly
delayed growth of disseminated Raji lymphoma cells in a
xenograft model and cleared tumors in 50% of the mice
[55]. In the second approach, doxorubicin (DOX) conju-
gated to LL1 (LL1-DOX) cleared disseminated Raji lymph-
oma xenografts in 90% of mice. More importantly, the DOX
dose used was 2.5% of the maximum tolerated dose of free
DOX [56]. Multiple myeloma is in general difficult to treat.
A single dose of LL1-DOX (IMMU-110, Immunomedics,
Inc.) cleared multiple myeloma xenografts in 70% of mice
and significantly prolonged survival [57].
The humanized form of LL1 (hLL1 or milatuzumab,
Immunomedics, Inc.) alone showed promising antitumor
effects in disseminated Raji and Daudi NHL xenograft
models [58], and in multiple myeloma xenograft models
[59]. Unlike the cell killing mechanism employed by ritux-
imab, milatuzumab-mediated elimination of tumor cells
does not involve antibody-dependent cell-mediated cyto-
toxicity (ADCC) or a complement-dependent cytotoxicity
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combined with a crosslinking antibody induces aggre-
gation of CD74 on the cell surface of CLL cells [60]. In
another report, crosslinked milatuzumab induced signifi-
cant apoptosis at 48 h, accompanied with activation of
caspase-8 and caspase-3 [58], suggesting the involvement
of an extrinsic (receptor-mediated) apoptotic pathway.
Our results suggest an explanation of those results. A
rapidly internalized CD74 (turnover completed in 10 mi-
nutes) can decrease the levels of surface Fas (Figure 4C-D)
through its internalization from the cell surface. Cross-
linked milatuzumab-induced aggregation of CD74 pre-
vents internalization of CD74 [60] and indirectly also
internalization of Fas, consequently increasing surface Fas
levels and sensitizing cells to Fas-mediated apoptosis
(Figure 5).Conclusions
We conclude that CD74 regulates Fas death receptor
signaling in lymphomas by decreasing the levels of Fas
receptor on the cell surface. The exact mechanism of
CD74-mediated down-regulation of surface Fas remains
unclear and deserves further investigation. Taking into ac-
count the frequent CD74 expression in cancers together
with the impaired Fas signaling associated with chemo-
resistance, we extrapolate that CD74 also contributes to
chemoresistance. Thus, addition of CD74-targeting anti-
body milatuzumab to current chemotherapy regimens can
offer new therapeutic interventions, as also suggested in
prior studies in multiple myeloma models [59]. Future
clinical studies should determine whether milatuzumab
can indeed restore Fas-signaling and chemotherapy responses
in lymphoma, CLL, and potentially other CD74-expressing
malignancies.Competing interests
Dr. Goldenberg is employed by and has stock in Immunomedics, Inc., which
has patented and owns the milatuzumab antibody used in this study. There
are no other potential conflict of interests relevant to this article.Authors’ contributions
ZB designed the experiments, generated and initially characterized
CD74-suppressed cell lines and wrote the manuscript; SW performed animal
and milatuzumab experiments; XA performed experiments with
chemotherapeutic agents; JFW analyzed surface expression of Fas; FKB and
LS performed Western blot analyses; AHR performed immunohistochemistry;
DMG, and FS designed the experiments and wrote the manuscript. All
authors read and approved the final manuscript.Acknowledgements
This work was supported by grants from the American Cancer Society
(118447-MRSG-10-052-01-LIB to ZB), the National Institutes of Health
(CA1206173, CA153170, CA158692, and DK091490 to F.S.), and the Leukemia
& Lymphoma Society (R6132-06 and R6187-09 to F.S.). We also thank the
Richard Spencer Lewis Foundation, patients and their families for their
support and willingness to join us in our efforts in developing new therapies
for lymphoma.Author details
1Department of Lymphoma and Myeloma, The University of Texas MD
Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.
2Immunomedics, Inc., Morris Plains, NJ 07950, USA. 3Center for Molecular
Medicine and Immunology, Garden State Cancer Center, Morris Plains, NJ
07950, USA.
Received: 29 July 2014 Accepted: 22 September 2014References
1. Shackelford DA, Strominger JL: Demonstration of structural polymorphism
among HLA-DR light chains by two-dimensional gel electrophoresis.
J Exp Med 1980, 151:144–165.
2. Jones PP, Murphy DB, Hewgill D, McDevitt HO: Detection of a common
polypeptide chain in I–A and I–E sub-region immunoprecipitates.
Mol Immunol 1979, 16:51–60.
3. Long EO, Strubin M, Wake CT, Gross N, Carrel S, Goodfellow P, Accolla RS,
Mach B: Isolation of cDNA clones for the p33 invariant chain associated
with HLA-DR antigens. Proc Natl Acad Sci U S A 1983, 80:5714–5718.
4. Becker-Herman S, Arie G, Medvedovsky H, Kerem A, Shachar I: CD74 is a
member of the regulated intramembrane proteolysis-processed protein
family. Mol Biol Cell 2005, 16:5061–5069.
5. Matza D, Lantner F, Bogoch Y, Flaishon L, Hershkoviz R, Shachar I: Invariant
chain induces B cell maturation in a process that is independent of its
chaperonic activity. Proc Natl Acad Sci U S A 2002, 99:3018–3023.
6. Lantner F, Starlets D, Gore Y, Flaishon L, Yamit-Hezi A, Dikstein R, Leng L,
Bucala R, Machluf Y, Oren M, Shachar I: CD74 induces TAp63 expression
leading to B-cell survival. Blood 2007, 110:4303–4311.
7. Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, Delohery T, Chen Y,
Mitchell RA, Bucala R: MIF signal transduction initiated by binding to
CD74. J Exp Med 2003, 197:1467–1476.
8. Stein R, Mattes MJ, Cardillo TM, Hansen HJ, Chang CH, Burton J, Govindan S,
Goldenberg DM: CD74: a new candidate target for the immunotherapy
of B-cell neoplasms. Clin Cancer Res 2007, 13:5556s–5563s.
9. Burton JD, Ely S, Reddy PK, Stein R, Gold DV, Cardillo TM, Goldenberg DM:
CD74 is expressed by multiple myeloma and is a promising target for
therapy. Clin Cancer Res 2004, 10:6606–6611.
10. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, Zhang J, Soden R,
Hayakawa M, Kreiman G, Cooke MP, Walker JR, Hogenesch JB: A gene atlas
of the mouse and human protein-encoding transcriptomes. Proc Natl
Acad Sci U S A 2004, 101:6062–6067.
11. Starlets D, Gore Y, Binsky I, Haran M, Harpaz N, Shvidel L, Becker-Herman S,
Berrebi A, Shachar I: Cell-surface CD74 initiates a signaling cascade
leading to cell proliferation and survival. Blood 2006, 107:4807–4816.
12. Ioachim HL, Pambuccian SE, Hekimgil M, Giancotti FR, Dorsett BH:
Lymphoid monoclonal antibodies reactive with lung tumors. Diagnostic
applications. Am J Surg Pathol 1996, 20:64–71.
13. Binsky I, Haran M, Starlets D, Gore Y, Lantner F, Harpaz N, Leng L,
Goldenberg DM, Shvidel L, Berrebi A, Bucala R, Shachar I: IL-8 secreted in a
macrophage migration-inhibitory factor- and CD74-dependent manner
regulates B cell chronic lymphocytic leukemia survival. Proc Natl Acad Sci
U S A 2007, 104:13408–13413.
14. Otten HG, van Ginkel WG, Hagenbeek A, Petersen EJ: Prevalence and
clinical significance of resistance to perforin- and FAS-mediated cell
death in leukemia. Leukemia 2004, 18:1401–1405.
15. Moriyama H, Yonehara S: Rapid up-regulation of c-FLIP expression by BCR
signaling through the PI3K/Akt pathway inhibits simultaneously induced
Fas-mediated apoptosis in murine B lymphocytes. Immunol Lett 2007, 109:36–46.
16. de Totero D, Montera M, Rosso O, Clavio M, Balleari E, Foa R, Gobbi M:
Resistance to CD95-mediated apoptosis of CD40-activated chronic
lymphocytic leukemia B cells is not related to lack of DISC molecules
expression. Hematol J 2004, 5:152–160.
17. de Totero D, Tazzari PL, Capaia M, Montera MP, Clavio M, Balleari E, Foa R,
Gobbi M: CD40 triggering enhances fludarabine-induced apoptosis of
chronic lymphocytic leukemia B-cells through autocrine release of tumor
necrosis factor-alpha and interferon-gama and tumor necrosis factor
receptor-I-II upregulation. Haematologica 2003, 88:148–158.
18. Kater AP, Dicker F, Mangiola M, Welsh K, Houghten R, Ostresh J, Nefzi A,
Reed JC, Pinilla C, Kipps TJ: Inhibitors of XIAP sensitize CD40-activated
Berkova et al. Journal of Experimental & Clinical Cancer Research 2014, 33:80 Page 9 of 10
http://www.jeccr.com/content/33/1/80chronic lymphocytic leukemia cells to CD95-mediated apoptosis.
Blood 2005, 106:1742–1748.
19. Williams JF, Petrus MJ, Wright JA, Husebekk A, Fellowes V, Read EJ, Gress RE,
Fowler DH: fas-mediated lysis of chronic lymphocytic leukaemia cells:
role of type I versus type II cytokines and autologous fasL-expressing
T cells. Br J Haematol 1999, 107:99–105.
20. Jones DT, Ganeshaguru K, Virchis AE, Folarin NI, Lowdell MW, Mehta AB,
Prentice HG, Hoffbrand AV, Wickremasinghe RG: Caspase 8 activation
independent of Fas (CD95/APO-1) signaling may mediate killing of
B-chronic lymphocytic leukemia cells by cytotoxic drugs or gamma
radiation. Blood 2001, 98:2800–2807.
21. Roue G, Lancry L, Duquesne F, Salaun V, Troussard X, Sola B: Upstream
mediators of the Fas apoptotic transduction pathway are defective in
B-chronic lymphocytic leukemia. Leuk Res 2001, 25:967–980.
22. Muller M, Scaffidi CA, Galle PR, Stremmel W, Krammer PH: The role of p53
and the CD95 (APO-1/Fas) death system in chemotherapy-induced
apoptosis. Eur Cytokine Netw 1998, 9:685–686.
23. Poulaki V, Mitsiades CS, Mitsiades N: The role of Fas and FasL as mediators
of anticancer chemotherapy. Drug Resist Updat 2001, 4:233–242.
24. Friesen C, Herr I, Krammer PH, Debatin KM: Involvement of the CD95
(APO-1/FAS) receptor/ligand system in drug-induced apoptosis in
leukemia cells. Nat Med 1996, 2:574–577.
25. Friesen C, Fulda S, Debatin KM: Induction of CD95 ligand and apoptosis
by doxorubicin is modulated by the redox state in chemosensitive- and
drug-resistant tumor cells. Cell Death Differ 1999, 6:471–480.
26. Eichhorst ST, Muerkoster S, Weigand MA, Krammer PH: The
chemotherapeutic drug 5-fluorouracil induces apoptosis in mouse thy-
mocytes in vivo via activation of the CD95(APO-1/Fas) system. Cancer Res
2001, 61:243–248.
27. Wang S, Maeng H, Young DP, Prakash O, Fayad LE, Younes A, Samaniego F:
K1 protein of human herpesvirus 8 suppresses lymphoma cell Fas-
mediated apoptosis. Blood 2007, 109:2174–2182.
28. Jenke AC, Eisenberger T, Baiker A, Stehle IM, Wirth S, Lipps HJ: The nonviral
episomal replicating vector pEPI-1 allows long-term inhibition of bcr-abl
expression by shRNA. Hum Gene Ther 2005, 16:533–539.
29. Berkova Z, Wang S, Wise JF, Maeng H, Ji Y, Samaniego F: Mechanism of Fas
signaling regulation by human herpesvirus 8 K1 oncoprotein. J Natl
Cancer Inst 2009, 101:399–411.
30. Tao RH, Berkova Z, Wise JF, Rezaeian AH, Daniluk U, Ao X, Hawke DH, Karp
JE, Lin HK, Molldrem JJ, Samaniego F: PMLRARalpha binds to Fas and
suppresses Fas-mediated apoptosis through recruiting c-FLIP in vivo.
Blood 2011, 118:3107–3118.
31. Liu F, Song Y, Liu D: Hydrodynamics-based transfection in animals by
systemic administration of plasmid DNA. Gene Ther 1999, 6:1258–1266.
32. Snow AL, Chen LJ, Nepomuceno RR, Krams SM, Esquivel CO, Martinez OM:
Resistance to Fas-mediated apoptosis in EBV-infected B cell lymphomas
is due to defects in the proximal Fas signaling pathway. J Immunol 2001,
167:5404–5411.
33. Gajate C, Mollinedo F: Edelfosine and perifosine induce selective
apoptosis in multiple myeloma by recruitment of death receptors and
downstream signaling molecules into lipid rafts. Blood 2007, 109:711–719.
34. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T,
Kitamura Y, Itoh N, Suda T, Nagata S: Lethal effect of the anti-Fas antibody
in mice. Nature 1993, 364:806–809.
35. Friesen C, Fulda S, Debatin KM: Deficient activation of the CD95 (APO-1/
Fas) system in drug-resistant cells. Leukemia 1997, 11:1833–1841.
36. Stel AJ, Ten Cate B, Jacobs S, Kok JW, Spierings DC, Dondorff M, Helfrich W,
Kluin-Nelemans HC, de Leij LF, Withoff S, Kroesen BJ: Fas receptor cluster-
ing and involvement of the death receptor pathway in rituximab-
mediated apoptosis with concomitant sensitization of lymphoma B cells
to fas-induced apoptosis. J Immunol 2007, 178:2287–2295.
37. Amoroso A, Hafsi S, Militello L, Russo AE, Soua Z, Mazzarino MC, Stivala F,
Libra M: Understanding rituximab function and resistance: implications
for tailored therapy. Front Biosci (Landmark Ed) 2011, 16:770–782.
38. Muller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, Friedman
SL, Galle PR, Stremmel W, Oren M, Krammer PH: p53 activates the CD95
(APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp
Med 1998, 188:2033–2045.
39. Friesen C, Fulda S, Debatin KM: Cytotoxic drugs and the CD95 pathway.
Leukemia 1999, 13:1854–1858.40. Timmer T, de Vries EG, de Jong S: Fas receptor-mediated apoptosis: a
clinical application? J Pathol 2002, 196:125–134.
41. Takahashi H, Feuerhake F, Kutok JL, Monti S, Dal Cin P, Neuberg D, Aster JC,
Shipp MA: FAS death domain deletions and cellular FADD-like interleukin
1beta converting enzyme inhibitory protein (long) overexpression:
alternative mechanisms for deregulating the extrinsic apoptotic pathway
in diffuse large B-cell lymphoma subtypes. Clin Cancer Res 2006,
12:3265–3271.
42. Mielgo A, van Driel M, Bloem A, Landmann L, Gunthert U: A novel
antiapoptotic mechanism based on interference of Fas signaling by
CD44 variant isoforms. Cell Death Differ 2006, 13:465–477.
43. Wise JF, Berkova Z, Mathur R, Zhu H, Braun FK, Tao RH, Sabichi AL, Ao X,
Maeng H, Samaniego F: Nucleolin inhibits Fas ligand binding and
suppresses Fas-mediated apoptosis in vivo via a surface nucleolin-Fas
complex. Blood 2013, 121:4729–4739.
44. Daniluk U, Kerros C, Tao RH, Wise JF, Ao X, Berkova Z, Samaniego F: The
peptide derived from the Ig-like domain of human herpesvirus 8 K1
protein induces death in hematological cancer cells. J Exp Clin Cancer Res
2012, 31:69.
45. Tamori Y, Tan X, Nakagawa K, Takai E, Akagi J, Kageshita T, Egami H, Ogawa
M: Clinical significance of MHC class II-associated invariant chain expres-
sion in human gastric carcinoma. Oncol Rep 2005, 14:873–877.
46. Cuthbert RJ, Wilson JM, Scott N, Coletta PL, Hull MA: Differential CD74
(major histocompatibility complex Class II invariant chain) expression in
mouse and human intestinal adenomas. Eur J Cancer 2009, 45:1654–1663.
47. Verjans E, Noetzel E, Bektas N, Schutz AK, Lue H, Lennartz B, Hartmann A,
Dahl E, Bernhagen J: Dual role of macrophage migration inhibitory factor
(MIF) in human breast cancer. BMC Cancer 2009, 9:230.
48. Meyer-Siegler KL, Iczkowski KA, Vera PL: Further evidence for increased
macrophage migration inhibitory factor expression in prostate cancer.
BMC Cancer 2005, 5:73.
49. Meyer-Siegler KL, Iczkowski KA, Leng L, Bucala R, Vera PL: Inhibition of
macrophage migration inhibitory factor or its receptor (CD74) attenuates
growth and invasion of DU-145 prostate cancer cells. J Immunol 2006,
177:8730–8739.
50. Koide N, Yamada T, Shibata R, Mori T, Fukuma M, Yamazaki K, Aiura K,
Shimazu M, Hirohashi S, Nimura Y, Sakamoto M: Establishment of
perineural invasion models and analysis of gene expression revealed an
invariant chain (CD74) as a possible molecule involved in perineural
invasion in pancreatic cancer. Clin Cancer Res 2006, 12:2419–2426.
51. Nagata S, Jin YF, Yoshizato K, Tomoeda M, Song M, Iizuka N, Kitamura M,
Takahashi H, Eguchi H, Ohigashi H, Ishikawa O, Tomita Y: CD74 is a novel
prognostic factor for patients with pancreatic cancer receiving
multimodal therapy. Ann Surg Oncol 2009, 16:2531–2538.
52. Kitange GJ, Carlson BL, Schroeder MA, Decker PA, Morlan BW, Wu W,
Ballman KV, Giannini C, Sarkaria JN: Expression of CD74 in high grade
gliomas: a potential role in temozolomide resistance. J Neurooncol 2010,
100:177–186.
53. Ong GL, Goldenberg DM, Hansen HJ, Mattes MJ: Cell surface expression
and metabolism of major histocompatibility complex class II invariant
chain (CD74) by diverse cell lines. Immunology 1999, 98:296–302.
54. Hansen HJ, Ong GL, Diril H, Valdez A, Roche PA, Griffiths GL, Goldenberg
DM, Mattes MJ: Internalization and catabolism of radiolabelled antibodies
to the MHC class-II invariant chain by B-cell lymphomas. Biochem J 1996,
320(Pt 1):293–300.
55. Ochakovskaya R, Osorio L, Goldenberg DM, Mattes MJ: Therapy of
disseminated B-cell lymphoma xenografts in severe combined immuno-
deficient mice with an anti-CD74 antibody conjugated with (111)indium,
(67)gallium, or (90)yttrium. Clin Cancer Res 2001,
7:1505–1510.
56. Griffiths GL, Mattes MJ, Stein R, Govindan SV, Horak ID, Hansen HJ,
Goldenberg DM: Cure of SCID mice bearing human B-lymphoma
xenografts by an anti-CD74 antibody-anthracycline drug conjugate.
Clin Cancer Res 2003, 9:6567–6571.
57. Sapra P, Stein R, Pickett J, Qu Z, Govindan SV, Cardillo TM, Hansen HJ, Horak
ID, Griffiths GL, Goldenberg DM: Anti-CD74 antibody-doxorubicin
conjugate, IMMU-110, in a human multiple myeloma xenograft and in
monkeys. Clin Cancer Res 2005, 11:5257–5264.
58. Stein R, Qu Z, Cardillo TM, Chen S, Rosario A, Horak ID, Hansen HJ,
Goldenberg DM: Antiproliferative activity of a humanized anti-CD74
Berkova et al. Journal of Experimental & Clinical Cancer Research 2014, 33:80 Page 10 of 10
http://www.jeccr.com/content/33/1/80monoclonal antibody, hLL1, on B-cell malignancies. Blood 2004,
104:3705–3711.
59. Stein R, Smith MR, Chen S, Zalath M, Goldenberg DM: Combining
milatuzumab with bortezomib, doxorubicin, or dexamethasone
improves responses in multiple myeloma cell lines. Clin Cancer Res 2009,
15:2808–2817.
60. Hertlein E, Triantafillou G, Sass EJ, Hessler JD, Zhang X, Jarjoura D, Lucas DM,
Muthusamy N, Goldenberg DM, Lee RJ, Byrd JC: Milatuzumab
immunoliposomes induce cell death in CLL by promoting accumulation
of CD74 on the surface of B cells. Blood 2010, 116:2554–2558.
doi:10.1186/s13046-014-0080-y
Cite this article as: Berkova et al.: CD74 interferes with the expression of
fas receptor on the surface of lymphoma cells. Journal of Experimental &
Clinical Cancer Research 2014 33:80.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
